A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies

High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these “high-risk” men may not be at significant...

Full description

Saved in:
Bibliographic Details
Published in:World journal of urology 2008-10, Vol.26 (5), p.475-480
Main Authors: Gonzalez, Joshua R., Laudano, Melissa A., McCann, Tara R., McKiernan, James M., Benson, Mitchell C.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Combined Modality Therapy
Gynecology. Andrology. Obstetrics
Humans
Lymph Node Excision
Male
Male genital diseases
Medical sciences
Medicine
Medicine & Public Health
Neoadjuvant Therapy
Nephrology
Nephrology. Urinary tract diseases
Oncology
Prostatectomy
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - radiotherapy
Prostatic Neoplasms - surgery
Prostatic Neoplasms - therapy
Review
Risk Factors
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these “high-risk” men may not be at significant risk of dying from their cancer. In this review, an attempt will be made to better define high-risk patients and help identify men at increased risk for mortality, not simply biochemical failure, after a diagnosis of localized prostate cancer. A review of available monotherapies as well as previously successful multimodality treatments will also be presented. Finally, this review will provide a glimpse into the future direction of high-risk prostate cancer multimodal therapy by providing a synopsis several current randomized clinical trials using effective systemic adjuvant therapies following local treatment.
ISSN:0724-4983
1433-8726
DOI:10.1007/s00345-008-0314-8